BR0309009A - Method for the treatment of mucus hypersecretion - Google Patents
Method for the treatment of mucus hypersecretionInfo
- Publication number
- BR0309009A BR0309009A BR0309009-4A BR0309009A BR0309009A BR 0309009 A BR0309009 A BR 0309009A BR 0309009 A BR0309009 A BR 0309009A BR 0309009 A BR0309009 A BR 0309009A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- mucus hypersecretion
- preparation
- kinase inhibitors
- inhalation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Abstract
"MéTODO PARA O TRATAMENTO DE HIPERSECREçãO DE MUCO". A invenção refere-se ao uso de inibidores de p38 cinase para a preparação de uma composição farmacêutica apropriada para inalação para o tratamento de hipersecreção de muco. Além disso, a invenção é dirigida a composições farmacêuticas apropriadas para inalação com inibidores de p38 cinase e aos métodos para a preparação dos mesmos."METHOD FOR TREATING HYPER DESCRIPTION". The invention relates to the use of p38 kinase inhibitors for the preparation of a suitable inhalation pharmaceutical composition for the treatment of mucus hypersecretion. Furthermore, the invention is directed to pharmaceutical compositions suitable for inhalation with p38 kinase inhibitors and methods for their preparation.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02007699 | 2002-04-05 | ||
PCT/EP2003/003434 WO2003084503A2 (en) | 2002-04-05 | 2003-04-02 | P38 kinase inhibitors for treating mucus hypersecretion_ |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0309009A true BR0309009A (en) | 2005-03-22 |
Family
ID=28685842
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0309009-4A Expired - Fee Related BR0309009A (en) | 2002-04-05 | 2003-04-02 | Method for the treatment of mucus hypersecretion |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1494645A2 (en) |
JP (1) | JP2005528374A (en) |
KR (1) | KR20040101398A (en) |
CN (1) | CN1658834A (en) |
AU (1) | AU2003224025A1 (en) |
BR (1) | BR0309009A (en) |
CA (1) | CA2479520A1 (en) |
IL (1) | IL163737A0 (en) |
MX (1) | MXPA04009605A (en) |
NZ (1) | NZ536278A (en) |
PL (1) | PL372963A1 (en) |
RU (1) | RU2004132847A (en) |
WO (1) | WO2003084503A2 (en) |
ZA (1) | ZA200406910B (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070010529A1 (en) * | 2003-05-19 | 2007-01-11 | Kanji Takahashi | Nitrogenous heterocyclic compounds and medical use thereof |
US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
WO2006137421A1 (en) * | 2005-06-21 | 2006-12-28 | Kyowa Hakko Kogyo Co., Ltd. | Agent for topical administration |
FR2903774B1 (en) * | 2006-07-17 | 2008-09-05 | Renault Sas | METHOD FOR VALIDATING A FUNCTIONING DIAGNOSTIC OF A DEVICE. |
GB0818033D0 (en) | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
BRPI0920707A2 (en) | 2008-10-02 | 2015-12-29 | Respivert Ltd | compounds |
US8299074B2 (en) | 2008-12-11 | 2012-10-30 | Respivert Ltd. | P38 MAP kinase inhibitors |
GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
CA3077499C (en) | 2017-10-05 | 2021-09-21 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
DE60014603T2 (en) * | 1999-03-12 | 2006-02-16 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | Heterocyclic urea and related compounds as anti-inflammatory agents |
JP2003500403A (en) * | 1999-05-21 | 2003-01-07 | サイオス,インコーポレーテッド | Indole-type derivatives as inhibitors of p38 kinase |
EP1218347A1 (en) * | 1999-08-19 | 2002-07-03 | Signal Pharmaceuticals, Inc. | Pyrazoloanthrone and derivatives thereof as jnk inhibitors and their compositions |
CA2385722A1 (en) * | 1999-09-17 | 2001-03-22 | Smithkline Beecham Corporation | Use of csaids in rhinovirus infection |
AU2001291013A1 (en) * | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
EP1337250A2 (en) * | 2000-10-19 | 2003-08-27 | SmithKline Beecham Corporation | Use of p38 inhibitors for the treatment of smoke inhalation |
MXPA03009361A (en) * | 2001-04-13 | 2004-01-29 | Boehringer Ingelheim Pharma | Compounds useful as anti-inflammatory agents. |
EP1453515A4 (en) * | 2001-11-09 | 2006-11-29 | Scios Inc | Method to treat cystic fibrosis |
-
2003
- 2003-04-02 KR KR10-2004-7015891A patent/KR20040101398A/en not_active Application Discontinuation
- 2003-04-02 NZ NZ536278A patent/NZ536278A/en unknown
- 2003-04-02 MX MXPA04009605A patent/MXPA04009605A/en unknown
- 2003-04-02 IL IL16373703A patent/IL163737A0/en unknown
- 2003-04-02 JP JP2003581743A patent/JP2005528374A/en active Pending
- 2003-04-02 WO PCT/EP2003/003434 patent/WO2003084503A2/en not_active Application Discontinuation
- 2003-04-02 BR BR0309009-4A patent/BR0309009A/en not_active Expired - Fee Related
- 2003-04-02 CA CA002479520A patent/CA2479520A1/en not_active Abandoned
- 2003-04-02 EP EP03720407A patent/EP1494645A2/en not_active Ceased
- 2003-04-02 CN CN038129884A patent/CN1658834A/en active Pending
- 2003-04-02 RU RU2004132847/15A patent/RU2004132847A/en not_active Application Discontinuation
- 2003-04-02 AU AU2003224025A patent/AU2003224025A1/en not_active Abandoned
- 2003-04-02 PL PL03372963A patent/PL372963A1/en not_active Application Discontinuation
-
2004
- 2004-08-31 ZA ZA200406910A patent/ZA200406910B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2479520A1 (en) | 2003-10-16 |
IL163737A0 (en) | 2005-12-18 |
NZ536278A (en) | 2007-05-31 |
WO2003084503A2 (en) | 2003-10-16 |
AU2003224025A1 (en) | 2003-10-20 |
KR20040101398A (en) | 2004-12-02 |
EP1494645A2 (en) | 2005-01-12 |
RU2004132847A (en) | 2006-08-20 |
PL372963A1 (en) | 2005-08-08 |
ZA200406910B (en) | 2006-06-28 |
CN1658834A (en) | 2005-08-24 |
JP2005528374A (en) | 2005-09-22 |
MXPA04009605A (en) | 2005-01-11 |
WO2003084503A3 (en) | 2004-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200300906A1 (en) | NEW SPYROTRICYCLIC DERIVATIVES AND THEIR APPLICATION AS PHOSPHODESTERASE-7 INHIBITORS | |
BR0108600A (en) | Compound, process for preparing it, pharmaceutical composition, process for preparing it, use of a compound, and methods for treating a chemokine-mediated disease and for treating an inflammatory disease | |
BRPI0207961B8 (en) | use of epothilone and capecitabine analogues to manufacture medicine to treat solid cancerous tumors and kit comprising said compounds. | |
BR0113776A (en) | Composition of selected fused pyrrolocarbazoles and method for treating and preventing various diseases using said composition | |
BRPI0407454A (en) | Pyrazoles and methods of preparing and using them | |
MEP90508A (en) | New pharmaceutical composition | |
BR0307429A (en) | Compound, use thereof, pharmaceutical composition, and method for treating h3 histamine receptor related disorders or diseases | |
EA200300776A1 (en) | FENETHANOLAMINE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | |
SE9800836D0 (en) | New Compounds | |
BRPI0407993A (en) | p38 inhibitors and methods for using them | |
BRPI0407922A (en) | isoquinoline derivatives and methods of use of these | |
MXPA05005223A (en) | Diaminotriazoles useful as inhibitors of protein kinases. | |
BR0311931A (en) | Compound, pharmaceutical composition, use of a compound, and method for treating an hppar-mediated disease or condition in a patient | |
ATE433973T1 (en) | AZOLYLAMINOAZINES AS INHIBITORS OF PROTEIN KINASES | |
BRPI0307351B8 (en) | compound, pharmaceutical composition, use of a compound, and, process for preparing a compound | |
BR0116370A (en) | Compound, pharmaceutical composition, use of a compound, and method of treating an hppar-mediated disease or condition in a patient. | |
BRPI0108395B8 (en) | pyrrolopyrimidinone derivatives, preparation and use processes | |
UY27755A1 (en) | NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND INHIBITORS. | |
TNSN06138A1 (en) | INHIBITORS OF THE MUTANT FORM OF KIT | |
DE60237528D1 (en) | NEW AMINOAZETIDIN, AMINOPYRROLIDIN AND AMINOPIPERIDINE DERIVATIVES | |
BR0309009A (en) | Method for the treatment of mucus hypersecretion | |
ATE452884T1 (en) | ARYLMETHYLAMINE DERIVATIVES FOR USE AS INHIBITORS OF TRYPTASE | |
BRPI0411864A (en) | combination of src kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases | |
YU75803A (en) | Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases | |
BR0309406A (en) | Pharmaceutical composition, preparation process, kit and methods for treating obesity, use of lipase composition and inhibitor, lipase inhibitor and glucomannan or konjac and their use and method of treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A E 7A ANUIDADES |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010. |